May 11, 2024, Hong Kong – Crosswire, a leader in cross-border investment and innovation, has announced a deepened partnership with Hongjitang, a leading biotech company in mainland China, to further advance the integration of biosciences and traditional Chinese medicine (TCM). This collaboration aims to develop and promote new health solutions, providing clients with more comprehensive health coverage.
The partnership will focus on combining cutting-edge biotechnology with TCM to create innovative health products and services. Leveraging Hongjitang’s extensive expertise in traditional medicine and Crosswire’s proficiency in finance and technology, this collaboration seeks to offer clients personalized and holistic health solutions.
“The fusion of traditional Chinese medicine and modern biosciences opens new frontiers in health management,” said Crosswire’s CEO. “Through our partnership with Hongjitang, we aim to deliver innovative health solutions that transform the landscape of health management.”
In addition, Crosswire plans to leverage this collaboration to drive advancements in health technology, including smart health management tools and personalized medical services, enhancing clients’ health experiences and overall quality of life.
